Bluebird bio Lays Out Planned Updates Ahead Of J.P. Morgan Healthcare Conference
Bluebird bio Inc (NASDAQ: BLUE) announced planned updates to be presented at the 40th Annual J.P.
Where bluebird bio Stands With Analysts
Within the last quarter, bluebird bio (NASDAQ:BLUE) has observed the following analyst ratings:
12 Health Care Stocks Moving In Wednesday’s After-Market Session
Gainers
Cognition Therapeutics (NASDAQ:CGTX) shares rose 14.9% to $6.62 during Wednesday's after-market session. The market value of their outstanding shares is at $145.8 million.
Mid-Day Market Update: Crude Oil Drops Over 5%; Society Pass Shares Jump
Midway through trading Monday, the Dow traded down 1.78% to 34,735.33 while the NASDAQ fell 1.43% to 14,952.69. The S&P also fell, dropping 1.59% to 4,547.26.
bluebird bio Announces Partial Clinical Hold For Patients Under 18 In Sickle Cell Gene Therapy Clinical Program
bluebird bio, Inc. (NASDAQ:BLUE) today announced that the FDA has placed its clinical program for lovotibeglogene autotemcel (lovo-cel) gene therapy for sickle cell disease (SCD) on partial clinical hold for patients
bluebird bio Saturday Highlighted New Data That Further Showed beti-cel Is A Potentially Curative 1-Time Gene Therapy For B-Thalassemia Patients Who Require Regular Transfusions Through Achievement Of Durable T1, Normal, Near-Normal Adult Hb Levels
Oral presentation featured in the ASH press program includes long-term data through August 2021 in patients who achieved transfusion independence (TI) (n=46) and remain transfusion-free through up to seven years of
22 Stocks Moving in Monday’s Pre-Market Session
Gainers
Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) rose 32.6% to $3.58 in pre-market trading after gaining more than 14% on Friday.